Why polynucleotides change clinic economics in 2026.
The aesthetic-injectables market split in two during 2025. On one side, the commodity HA-filler tier where unit prices have compressed and patient pull has plateaued. On the other, the polynucleotide tier where unit prices hold, repeat-protocol structures favour the clinic, and patient lifetime value has risen materially. The clinics that adjusted their stock-mix early have outperformed. This is the maths.
The unit economics shift
| Category | Trade unit cost | Typical clinic price | Sessions per protocol | Annual patient revenue |
|---|---|---|---|---|
| HA filler 1ml | EUR 25 to 50 | EUR 350 to 500 | 1 to 2 | EUR 350 to 1,000 |
| Profhilo 2ml | EUR 89 | EUR 350 to 450 | 2 | EUR 700 to 900 |
| Sunekos 200 | EUR 98 | EUR 250 to 350 per session | 3 | EUR 750 to 1,050 |
| Polynucleotide 2ml | EUR 61 to 100 | EUR 350 to 500 per session | 3 to 4 | EUR 1,050 to 2,000 |
The polynucleotide tier delivers materially higher annual patient revenue because the protocol structure is three to four sessions rather than one to two, the unit clinic pricing has held, and the patient-recognition has caught up. By 2026 most patients in Dublin and Cork premium clinics arrive asking for polynucleotides by name.
What the right product mix looks like
For a generalist aesthetic clinic running 200 to 400 patient encounters per year, our stock-mix recommendation in 2026 is:
- 40 percent polynucleotides (Nucleofill range, Plinest, Plinest Eye)
- 25 percent HA fillers (Aessoa, Regenovue, Lumifil for lip)
- 20 percent skin boosters and bio-remodellers (Profhilo, Sunekos)
- 10 percent fat dissolvers (Aqualyx, Lemon Bottle, Lipo Lab)
- 5 percent mesotherapy and under-eye (Vitaran Eyes, Jalupro Young Eye, Kairax)
Adjust for the clinic's patient demographic. Periorbital-heavy practices weight Sunekos and under-eye boosters higher. Body-contouring practices weight fat dissolvers higher. The 40 percent polynucleotide weighting is the headline change from 2024 mix.
Stock-management implication
Polynucleotide protocols run three to four sessions over six to ten weeks. The clinic carries patient bookings for that whole window. A stock-out at week six is a reputation event, not a logistics inconvenience. The OFAB position: keep polynucleotide stock above the next 30-day demand at all times. Same-day Coolock dispatch makes this easier than it was in 2024 when most Irish clinics held a six-week buffer because their UK supplier's customs window was unreliable.
Patient-conversation framing
The maths-side is straightforward; the patient-conversation side is where most clinics under-convert. Polynucleotides are described well in regenerative-medicine framing (cell turnover, fibroblast support) and poorly in commodity-aesthetic framing (just another injection). The clinics that have grown the polynucleotide line in 2026 have invested in the patient-education layer rather than the discount layer.
Discounting polynucleotides is a strategic error. The category is supply-constrained on the manufacturer side and patient-recognition is still rising. Hold price; invest in education.
Three-month plan for a clinic adding polynucleotides
- Week 1 to 2. Stock Nucleofill Medium (EUR 64 ex VAT) and Plinest (EUR 72 ex VAT). One unit each per booked-in protocol session for the first month. Place order.
- Week 3 to 4. Train the front-of-house consultation language. Build the three-session protocol pricing card. Photograph baseline and four-week-post on the first three patients.
- Week 5 to 8. Add Plinest Eye for the periorbital indication. Layer with Sunekos 200 where indicated.
- Week 9 to 12. Review the patient-mix data. Adjust the polynucleotide weighting between Nucleofill (price-aware) and Plinest (premium tier).
The OFAB stock position
OFAB carries the full Nucleofill range (Soft Plus, Medium, Strong), Plinest, Plinest Eye, NEWGyn, and Kairax in stock at Coolock. Same-day dispatch on weekday orders before 12:30. Apply for trade account to access pricing.